What will be the domestic selling price of Erlotinib in 2025?

As of2025, Erlotinib (Erlotinib) has been successfully launched in China and has been included in the national medical insurance directory, bringing higher accessibility to patients with lung cancer and other indications. With the support of the medical insurance reimbursement policy, the price of erlotinib provided by domestic hospitals has been significantly reduced, and the patient's out-of-pocket payment is usually around a few hundred yuan. However, due to slight differences in medical insurance policies across regions, patients are advised to consult the local hospital pharmacy or medical insurance office to obtain more accurate price information before purchasing.

At present, the main circulation in the domestic market is the generic version of erlotinib, which has the same efficacy as the original drug and is more affordable. The price after medical insurance payment is a benefit for patients with limited economic conditions, especially for patients with non-small cell lung cancer (NSCLC). Erlotinib is widely used as a first-line or late-line targeted therapy drug. Its affordable price helps improve the persistence of long-term medication and treatment compliance.

In foreign markets, erlotinib also has original drugs and multiple generic versions in circulation. Generic drugs produced by pharmaceutical companies in countries such as India and Laos are particularly common. Among them, the Lao version of erlotinib has attracted much attention because of its low price. For example, the price of 150mg erlotinib generic drug produced in Laos is about 400 RMB per box. Although these generic drugs usually do not have marketing authorization in China, they are still available to patients through legal cross-border medical platforms or overseas pharmacy channels and serve as complementary options for domestic treatment.

Taken together, whether you purchase it within the domestic medical insurance system or obtain generic drugs through overseas purchasing channels, the price of erlotinib in 2025 will be relatively affordable. For lung cancer patients who need long-term medication, choosing drugs covered by medical insurance can provide financial protection. For some patients who are not covered by reimbursement or those who want to save money, generic drugs are a cost-effective alternative. However, when choosing overseas drugs, you must pay attention to the formality of the channels and the quality of the drugs to ensure safety and effectiveness.

Reference:https://en.wikipedia.org/wiki/Erlotinib